NCT/Study#
NCT04482699 /
RAPA501ALLOCOVID19
RAPA-501-ALLO-COVID-19, PI: Dr. Donato, Title: Phase I/Phase II Trial of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-Allo) Therapy for Severe, Post-Intubation Stage 3 COVID-19 Disease
DISEASE GROUP:
Transplant
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
